← Product Code [JJX](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX) · K103553 # LIFESCAN ONETOUCH SELECT / ULTRA / VITA GLUCOSE CONTROL SOLUTION (K103553) _Bionostics, Inc. · JJX · Feb 10, 2011 · Clinical Chemistry · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX/K103553 ## Device Facts - **Applicant:** Bionostics, Inc. - **Product Code:** [JJX](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX.md) - **Decision Date:** Feb 10, 2011 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 862.1660 - **Device Class:** Class 1 - **Review Panel:** Clinical Chemistry ## Indications for Use LifeScan OneTouch Ultra Control Solution is intended for use to verify the performance of the LifeScan OneTouch Ultra Family and the OneTouch Ping™ Meter Remote blood glucose monitoring test systems at a glucose level printed on the test strip vial. The LifeScan OneTouch Ultra Control Solution is intended for use by healthcare professionals and people with diabetes mellitus at home. LifeScan OneTouch Select Control Solution is intended for use to verify the performance of the LifeScan OneTouch Select blood glucose monitoring test system at a glucose level printed on the test strip vial. The LifeScan OneTouch Select Control Solution is intended for use by healthcare professionals and people with diabetes mellitus at home. LifeScan OneTouch Vita Control Solution is intended for use to verify the performance of the LifeScan OneTouch Vita blood glucose monitoring test system at a glucose level printed on the test strip vial. The LifeScan OneTouch Vita Control Solution is intended for use by healthcare professionals and people with diabetes mellitus at home. ## Device Story Control solution for blood glucose monitoring systems; verifies test system performance. Buffered aqueous solution containing D-glucose; viscosity modifiers; preservatives; dye. Applied to test strips by healthcare professionals or patients at home; mimics whole blood response. Output is a glucose reading compared against the target level printed on the test strip vial. Used to ensure accuracy of glucose monitoring systems; helps patients and clinicians confirm device reliability. ## Clinical Evidence No clinical data. Bench testing only, including closed bottle shelf-life stability, stability after opening (use-life), transport stability, and test response verification. ## Technological Characteristics Viscosity-adjusted, aqueous glucose control solution. Contains D-glucose, buffer, viscosity modifier, preservative, and dye. No hazardous, human, or animal-derived components. Packaged in 6 mL LDPE vials with dispensing tip and cap. Optimized to simulate whole blood response on LifeScan blood glucose test systems. ## Regulatory Identification A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls. ## Predicate Devices - OneTouch Ultra Control ([K022769](/device/K022769.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K103553 FEB 1 0 2011 # Quality Solut ## 510(k) Summary1 #### Submitter's name, address (a) (1) Bionostics, Inc. 7 Jackson Road Devens, MA 01434 ## Contact Person 10 February 2011 Randy Byrd VP, Chief Technical Officer (978) 772-7070 x 272 Date of preparation of this summary: - (2) Device trade or proprietary name: LifeScan OneTouch Select Control Solution LifeScan OneTouch Ultra Control Solution LifeScan OneTouch Vita Control solution ### Device common or usual name or classification name: גור Single (Specified) Analyte Control, All Types, Assayed and Unassayed | REGULATION MEDICAL
SPECIALTY | REGULATION
NUMBER | CLASS | REGULATION DESCRIPTION | |---------------------------------|----------------------|-------|------------------------| | Chemistry | 862.1660 | II | Glucose Control | #### l, Substantial Equivalence LifeScan OneTouch Select, Ultra and Vita Control Solutions are substantially equivalent in function, safety and efficacy to currently marketed devices for the same intended use as shown in the following tables: | Characteristic | Predicate Device | Proposed Device | |-------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------| | Name: | OneTouch Ultra Control | OneTouch Select Control
OneTouch Ultra Control
OneTouch Vita Control | | 510(k), Date: | K022769, 11.13.2002 | | | Number of levels: | 1, typical fasting glucose | 1, typical fasting glucose | | Analytes: | glucose | glucose | | Container: | 6 mL LDPE vial with dispensing tip
and cap | 6 mL LDPE vial with dispensing tip
and cap | | Fill volume: | 4 mL | 4 mL | | Color: | red | red | | Matrix: | Buffered, aqueous solution of D-
Glucose, viscosity modifier,
preservatives and other, non-
reactive ingredients. | Buffered, aqueous solution of D-
Glucose, viscosity modifier,
preservatives and other, non-
reactive ingredients. | | Brands: | OneTouch Ultra, OneTouch
Select, OneTouch Vita | Unchanged: OneTouch Ultra,
OneTouch Select, OneTouch Vita | LifeScan, OneTouch, OneTouch Select and OneTouch Vita are registrered trademarks of Johnson & Johnson Corporation, New Brunswick, NJ, USA. 4 This summary of safety and effectiveness is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. {1}------------------------------------------------ #### ll. Description of the new device The control solution is a buffered aqueous solution with glucose containing no ingredients of biological origin, or in concentrations qualifying as a controlled product under the Controlled Products Regulation. The primary differences in the composition of the OneTouch Select, Ultra and Vita branded Control Solutions to that of the current, · OneTouch Ultra Control are the type and relative content of buffer system, type and relative content of the viscosity adjusting agent, type and relative content of the preservative system, a lower concentration of dye, and a relative reduction in the content of water. The OneTouch Ultra control is currently in use with all LifeScan blood glucose test systems under the OneTouch Ultra, OneTouch Select and OneTouch Vita brands. The new control solution is reformulated for optimized performance across these various brands of test strips, and will be distributed under the same brands as the current Ultra control. #### (a) (1) Intended use of the device LifeScan OneTouch Ultra Control Solution is intended for use to verify the performance of the LifeScan OneTouch Ultra Family and the OneTouch Ping™ Meter Remote blood glucose monitoring test systems at a glucose level printed on the test strip vial. The LifeScan OneTouch Ultra Control Solution is intended for use by healthcare professionals and people with diabetes mellitus at home. LifeScan OneTouch Select Control Solution is intended for use to verify the performance of the LifeScan OneTouch Select blood glucose monitoring test system at a glucose level printed on the test strip vial. The LifeScan OneTouch Select Control Solution is intended for use by healthcare professionals and people with diabetes mellitus at home. LifeScan OneTouch Vita Control Solution is intended for use to verify the performance of the LifeScan OneTouch Vita blood glucose monitoring test system at a glucose level printed on the test strip vial. The LifeScan OneTouch Vita Control Solution is intended for use by healthcare professionals and people with diabetes mellitus at home. #### (a) (2) Technological characteristics of the device. This material consists of viscosity-adjusted, aqueous glucose control solution prepared with a single concentration of D-glucose with recovery on the test systems in the range typically considered normal, fasting glucose for a non-diabetic person. This solution has been optimized to simulate the response of whole blood on the LifeScan OneTouch Ultra, Select and Vita branded blood glucose test systems. The solution contains no hazardous, human or animal derived components. {2}------------------------------------------------ - (b) (1) Summary of non-clinical tests submitted with the premarket notification for the device. Tests were conducted to verify specific performance requirements: - a) Closed bottle stability (Shelf-life) - b) Stability after opening (Use-life) - c) Transport Stability - d) Test response - Summary of clinical tests submitted with the premarket notification for the device. (b) (2) N/A - (b) (3) Conclusions drawn from the clinical and non-clinical trials. Comparison of technological characteristics, formulation and intended use to predicate devices listed in this summary support the claim of substantial equivalence. {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of an eagle or bird with outstretched wings. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 FEB 1 0 2011 Bionostics, Inc. c/o Randy Byrd Vice President & Chief Technical Officer 7 Jackson Road Devens, MA 01434 Re: k103553 > Trade Name: LifeScan OneTouch Select Control Solution, LifeScan OneTouch Ultra Control Solution, LifeScan OneTouch Vita Control Solution Regulation Number: 21 CFR §862.1660 Regulation Name: Quality control material Regulatory Class: Class I, reserved Product Code: JJX Dated: December 2, 2010 Received: December 3, 2010 Dear Mr. Byrd: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820). {4}------------------------------------------------ Page 2 - lf you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, CJC. Courtney Harper, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ ## Indications for Use 510(k) Number: K103553 Device Name: Indications for Use: LifeScan® OneTouch® Select® Control Solution The LifeScan OneTouch Select Control Solution is intended for use to verify the performance of the LifeScan OneTouch Select blood glucose monitoring test system at a glucose level printed on the test strip vial. The LifeScan OneTouch Select Control Solution is intended for use by healthcare professionals and people with diabetes mellitus at home. For In Vitro Diagnostic Use Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) AND/OR Concurrent of CDRH, Office of Device Evaluation (OIVD) Carol Benson Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) K103553 Page 1 of 3 {6}------------------------------------------------ ## Indications for Use 510(k) Number: K103553 LifeScan® OneTouch® Ultra® Control Solution Device Name: Indications for Use: The LifeScan OneTouch Ultra Control Solution is intended for use to verify the performance of the LifeScan OneTouch Ultra Family and the OneTouch Ping™ Meter Remote blood glucose monitoring test systems at a glucose level printed on the test strip vial. The LifeScan OneTouch Ultra Control Solution is intended for use by healthcare professionals and people with diabetes mellitus at home. For In Vitro Diagnostic Use Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED) AND/OR Concurrent of CDRH, Office of Device Evaluation (OIVD) Carol Benson Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) K103553 {7}------------------------------------------------ ## Indications for Use K103553 510(k) Number: Device Name: Indications for Use: LifeScan® OneTouch® Vita® Control Solution The LifeScan OneTouch Vita Control Solution is intended for use to verify the performance of the LifeScan OneTouch Vita blood glucose monitoring test system at a glucose level printed on the test strip vial. The LifeScan OneTouch Vita Control Solution is intended for use by healthcare professionals and people with diabetes mellitus at home. For In Vitro Diagnostic Use Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) AND/OR Concurrent of CDRH, Office of Device Evaluation (OIVD) Carl Benson Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) K103553 --- **Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX/K103553](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/JJX/K103553) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com